TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02670785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Capsule (EVC)
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Capsule (EVC)
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Capsule (EVC)
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
Study: NCT01156415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178
Study: NCT03717194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
Study: NCT03883646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention
Description: Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
Study: NCT02320071

Intervention type: OTHER
Intervention: Examination of abdominal wall strength changes over time
Study: NCT01628770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000
Description: Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: 200mg twice daily
Study: NCT05122858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS guided biliary drainage
Description: A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
Study: NCT01875887

Intervention type: PROCEDURE
Intervention: rapid prototyping technology
Description: Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
Study: NCT04055233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polihexanide; Serasept
Description: Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl; saline
Description: Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.
Study: NCT01320722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D ergocalciferol
Description: 50,000 unit soft gel capsule once per week for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo soft gel once per week for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
Study: NCT03588260

Intervention type: OTHER
Intervention: no intervention - cross-sectional observational only
Description: no intervention - cross-sectional observational only

Intervention type: OTHER
Intervention: no intervention - cross-sectional observational only
Description: no intervention - cross-sectional observational only
Study: NCT04614857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclined treadmill gait
Description: All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
Study: NCT02451644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer
Description: patient will cary pedometer
Study: NCT00943423

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved Field Radiotherapy
Description: IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No further treatment
Study: NCT03004599

Intervention type: DEVICE
Group type: OTHER
Intervention: SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System
Description: Transcatheter Aortic Valve Implantation via Transfemoral Approach
Study: NCT01543685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 40 mg TID capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 40 mg BID capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 20 mg TID capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 200 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT02015351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
Study: NCT03645616

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: First day: Participants undertook 6-minute walk test. There was a 30-minute interval between the first and second test, when the patient was asked to rest. During the resting period, they respond a pain intensity, functional capacity and physical activity level questionnaire.~Second day: the participants repeated the test and questionnaires.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 10 meters walk test
Description: First day: After the second 6-minute walk test the participants perform the 10-meter walk test, the test must be performed three times with a 30-second interval, at the end the average test velocity.~Second day: the participants repeated the test.
Study: NCT00365417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m\^2 IV every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 IV every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Following clinical response assessment, 650 mg/m\^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
Study: NCT03645616

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 30 Second Sit to Stand Test
Description: At the end of the tests the participants perform the 30 Second Sit to Stand Test on the first and second day.
Study: NCT01603667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
Study: NCT04587258

Intervention type: BEHAVIORAL
Intervention: Informational videos and social media campaigns encouraging cancer screening.
Description: Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
Study: NCT00365417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Following clinical response assessment, 75 mg/m\^2 IV every 21 days x 4 cycles
Study: NCT01021657

Intervention type: PROCEDURE
Intervention: trabeculectomies, non penetrating deep sclerectomies
Study: NCT02926937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet;~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet;~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet;~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: tablet;~Route of administration: oral
Study: NCT00156650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Testosterone (T) gel 10 g daily for 6 months
Study: NCT04505124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FutureMe App
Description: The FutureMe app provides visual and consequential feedback through a future-self avatar, meaning that the avatar changes its body shape and some additional characteristics based on the participants' activity and food purchasing behaviors. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
Study: NCT00156650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Testosterone (T) gel 10 g daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medroxyprogesterone
Description: 300 mg IM every 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medroxyprogesterone
Description: 300 mg IM every 3 months
Study: NCT02463019

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir Disoproxil Fumarate
Study: NCT03908307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZURDEX
Description: Implant 700 μg
Study: NCT04505124

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TrackingApp
Description: The Control Conventional Tracking app provides numeric and factual feedback through conventional data-dashboards. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
Study: NCT02028455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Description: Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Description: Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Description: Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Description: Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Description: Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
Study: NCT01291160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiflo
Description: During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Moist Wound Therapy
Description: During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
Study: NCT02273427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat meal
Study: NCT02028455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
Description: Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
Study: NCT02273427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fat meal
Study: NCT00493285

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-534
Description: Multiple doses of MEDI-534 or Placebo at 10\^4 TCID50
Study: NCT00062868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Group A)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Group B)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2
Study: NCT00493285

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-534
Description: Multiple doses of MEDI-534 or Placebo at 10 \^5 TCID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-534
Description: Multiple doses of MEDI-534 or Placebo at 10\^6 TCID50.
Study: NCT00062868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Group C)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP2 CTLs (ALSCER - Group A)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP2 CTLs (ALSCER - Group B)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP2 CTLs (ALSCER - Group C)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Expansion - Group A)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2
Study: NCT00062868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (ALCI - Expansion Group B)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2
Study: NCT03001739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urapidil Hydrochloride Injection
Description: Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urapidil Hydrochloride Injection
Description: Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
Study: NCT04304248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel, Carboplatin, Toripalimab
Description: Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
Study: NCT03636230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Monitoring
Description: Remote Monitoring only
Study: NCT04147533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib withdrawal
Description: withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial